Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RANK (CD265) Monoclonal Antibody (8H8B2)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA548653
Description
RANK (CD265) Monoclonal Antibody for Western Blot, Flow, ELISA
RANK is a member of the tumor necrosis factor receptor (TNFR) family. The full length mouse RANK cDNA encodes a type I transmembrane protein with an extracellular and a cytoplasmic domain. The extracellular domain contains two potential N-linked glycosylation sites. RANK shares significant amino acid homology with other members of the TNFR family in its extracellular four cysteine-rich repeats. Human and murine RANK share 81% amino acid identity in their extracellular domains.
Specifications
RANK (CD265) | |
Monoclonal | |
1 mg/mL | |
PBS with 0.05% sodium azide | |
Q9Y6Q6 | |
TNFRSF11A | |
Purified recombinant fragment of human TNFRSF11A (AA: extra 30-212) expressed in E. Coli. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG1 |
ELISA, Flow Cytometry, Western Blot | |
8H8B2 | |
Unconjugated | |
TNFRSF11A | |
CD265; FEO; LOH18CR1; loss of heterozygosity, 18, chromosomal region 1; Ly109; mRANK; ODFR; OFE; OPTB7; Osteoclast differentiation factor receptor; OSTS; Paget disease of bone 2; PDB2; Rank; receptor activator of NF-kappaB; receptor activator of NF-KB; receptor activator of nuclear factor-kappa B; RGD1563614; TNF receptor superfamily member 11a; Tnfrsf11a; TRANCER; TRANCE-R; tumor necrosis factor receptor superfamily member 11A; tumor necrosis factor receptor superfamily member 11a, NFKB activator; tumor necrosis factor receptor superfamily, member 11a, NFKB activator | |
Mouse | |
Protein G | |
RUO | |
8792 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction